– First Phase 3 HIV Prevention Trial to Show Zero Infections –
– Independent Data Monitoring Committee Recommended That Gilead Stop the Blinded Phase of the PURPOSE 1 Trial at Interim Analysis and Offer Open-Label Lenacapavir to All Participants –
Gilead Sciences Canada Announces Phase 3 PURPOSE 1 Trial Results; Lenacapavir Shows 100% Efficacy in HIV Prevention for Cisgender Women; Data Monitoring Committee Recommends Offering Open-Label Lenacapavir to All Participants
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.